Rimonabant Clinical Study

The clinical studies of the miraculous diet wonder Acomplia (Rimonabant) had proved its mettle as the new leader of the diet pill market. According to studies patients who were treated for one year with Acomplia(Rimonabant) 20 mg per day lost 8.6 kg (almost 20 lbs.) as compared to 2.3 kg (5 lbs.) loss with placebo (p<0.001).

Using Phentermine for Obesity – Have you tried Acomplia?

Now that a promising new prescription anti-obesity drug, rimonabant, is actually available in the U.K., Germany and several other countries, the launch of the most anticipated weight-loss medication since Fen-phen is generating a great deal of excitement among millions of obese and seriously overweight Americans and Europeans. The drug, marketed in Europe as Acomplia, ultimately is expected to reach the United States under the name Zimulti. Whatever the trade name, rimonabant has been hailed by some doctors on the basis of clinical trials as a major breakthrough in treating obesity.

So why don’t you try ‘The Miraculous Diet Pill – ACOMPLIA’, the best way to loose weight safely!

Acomplia Diet Pill: Sick and tired of short term weight loss with Phentermine!! Want to try something which is really dependable and beneficial in the long run? Try Acomplia diet pill! Acomplia is all set to surprise the weight loss drug market. The dual advantage of Acomplia helps people lose weight and is also a wondrous aid for smoking cessation. In fact Acomplia’s arrival in UK was treated as the arrival of a sure shot medication for the treatment of obesity. Acomplia is a prescription weight reducing pill and hence offers its users the full security and reliability through its usage.

Acomplia is your weight loss partner and if taken religiously offers a 5-15% of weight reduction in a very short span of time. What else do you expect from a weight loss pill. Buy Acomplia…buy weight loss

Obesity and Phentermine don’t work together; the best way to achieve proper weight loss is eating a nutritionally balanced diet and incorporate some moderate exercise everyday.

Phentermine Diet Pill is suitable for short term weight loss. Before you start taking this medication, think about the same. Like all medicines, Phentermine also tends to cause some side effects such as irritability, nervousness, sweating, dry mouth, nausea, constipation, and headache which were reported by the users of Phentermine. You have to be cautious that you don’t get dependent on this medication and most importantly don’t get addicted to its intake. Phentermine can also lead to few rare side effects which are generally not spoken about. Since Phentermine is used for a short time frame, people generally gain the lost weight after they stop taking phentermine.

Still confused between Acomplia and Phentermine ??

Nearly 75% (p<0.001 vs. placebo) of patients treated for one year with ACOMPLIA(TM) 20 mg lost over 5% of their body weight as compared to 41.8% (p = 0.002 vs. placebo) of patients on ACOMPLIA(TM) 5 mg and 27.6% of patients in the placebo group. Moreover, 44.3% (p<0.001 vs. placebo) lost more than 10% of their body weight when treated for one year with ACOMPLIA(TM) 20 mg vs. 16.3% of patients on ACOMPLIA(TM) 5 mg or 10.3% of patients on placebo.

In addition to weight loss, RIO-Lipids was designed to assess a number of associated important cardiovascular risk factors. All improvements in risk factors were statistically significant vs. the control group. In fact, the number of patients diagnosed as having metabolic syndrome1 at baseline (52.9%) was reduced by half (25.8%) after treatment with ACOMPLIA(TM) 20 mg (p<0.0001 compared to placebo). Study findings for rimonabant 20 mg include:

  • Waist circumference reduction of 9.1 cm (3.5 inches) in patients treated for a year (completers) with rimonabant 20 mg (p<0.001 vs. placebo).
  • Average increase of 23% in HDL-cholesterol in completers (p<0.001 vs. placebo).
  • Average reduction of 15% in triglycerides in completers (p<0.001 vs. placebo).
  • A positive shift in LDL particle size, with a reduction (p=0.002 vs. placebo) in the proportion of smaller dense atherogenic LDL particles, which are associated with cardiovascular risk, and an increase (p<0.001 vs. placebo) in the proportion of larger, less atherogenic LDL particles.